Skip to main content
. 2021 Sep 10;22(18):9804. doi: 10.3390/ijms22189804

Figure 3.

Figure 3

Anticancer therapeutic potential of Mogamulizumab (KW-0761). Mogamulizumab is shown in Figure 4. The antibody is prepared by glycoengineering and is defucosylated, enhancing the ADCC response promoted by cytotoxic T and NK cells. Elimination of CCR4+ Treg cells further enhances the immune response of cytotoxic T cells against the tumor cells.